Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2017. The document serves as a report of foreign issuer transactions, specifically detailing changes in shareholdings for Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them (PCAs). The filing does not contain operational updates, strategic shifts, or general business context beyond the notification of these specific equity transactions.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to the execution price of share transactions:
- Ordinary Shares Price: GBP 16.2437 per share.
- American Depositary Shares (ADS) Price: USD 40.57 per ADS.
Material Changes Versus Prior Period
No material changes to the company's financial position or operations are reported in this filing. The document exclusively reports the sale or withholding of shares by executives to meet tax liabilities following the vesting of awards granted in 2012, 2014, and 2015 under the 2009 Performance Share Plan. There is no comparative data provided against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, contingencies, or unusual items. The scope is strictly limited to regulatory disclosure of insider trading activity related to tax obligations.
Important Facts for Investor Verification
- Transaction Nature: All reported transactions were sales or withholdings of shares specifically to meet tax liabilities arising from the vesting of performance share awards.
- Key Executives Involved: Transactions were reported for Sir Andrew Witty (CEO), Ms. E. Walmsley (CEO Designate), Mr. S. Dingemans (CFO), and several other senior officers.
- Transaction Volume: Sir Andrew Witty sold an aggregated total of 64,664 Ordinary Shares. Other executives sold or withheld varying quantities of Ordinary Shares or ADSs.
- Market Venue: Ordinary Share transactions were conducted on the London Stock Exchange (XLON); ADS transactions were not attributed to a specific exchange venue in the text.
- Limitation of Scope: Investors should note that this filing does not contain financial results or strategic updates; those are typically found in Form 20-F or quarterly earnings releases.